News
-
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010’s API
Onco-Innovations Limited completes analytical reference standard preparation program for A83B4C63 in support of ONC010, enhancing quality infrastructure and analytical consistency. Achievements in CMC and analytical development strengthen ONC010 platform -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
Onco-Innovations Limited announces non-brokered private placement financing for CAD$5,000,000 with institutional investors. Offering consists of 6,764,070 units at CAD$0.7392/unit. Expected closing on July 15, 2026 -
-
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010
Onco-Innovations announces polymer process development and analytical characterization activities for ONC010 nanoparticle inhibitor in collaboration with Nanosoft, strengthening future GMP manufacturing and clinical development -
